Recent advancements in genome-wide analyses and RNA-sequencing technologies led to the discovery of small noncoding RNAs, such as microRNAs (miRs), as well as both linear long noncoding RNAs (lncRNAs) and circular long noncoding RNAs (circRNAs). The importance of miRs and lncRNAs in the treatment, prognosis and diagnosis of cardiovascular diseases (CVDs) has been extensively reported. We also previously reviewed their implications in therapies and as biomarkers for CVDs. More recently, circRNAs have also emerged as important regulators in CVDs. CircRNAs are circular genome products that are generated by back splicing of pathophysiological functions. CircRNAs have been shown to be key regulators of CVDs such as myocardial infarction, atherosclerosis, biomarkers for CVDs. In this review, we summarize the current state of the literature on circRNAs, starting with their biogenesis and global mechanisms of actions. We then provide a synopsis of their involvement in various CVDs. Lastly, we emphasize the great potential of circRNAs as biomarkers for the early detection of CVDs, and discuss several patents and recent papers that highlight the utilization of circRNAs as promising biomarkers.
Introduction
Cardiovascular disease (CVD) is a major killer of the human population in the USA and the world. It is estimated that approximately 100 million American adults (>1 in 3) have million) have been diagnosed with heart disease. By the some form of CVD advancements in disease management have been directed development of platforms for early detection and the possible biomarkers have been discovered and utilized in clinical set tings. According to the American Association for Clinical used in the clinic are cardiac troponin and creatine kinase (CK). Cardiac troponin diagnoses myocardial infarction; its . CK is mostly used to diagnose a second myocardial infarction occurring shortly injury occurs .
With the advancements in technology and the development regulate the function of genes and therefore modulate a vast number of physiological and pathological processes. Based roles of circRNAs and how they regulate cardiovascular pathology.
Global mechanisms of circular RNA function
MiRNA sponge: Cytoplasmic circRNAs are shown to contain binding sites for enous RNAs (ceRNAs) . Because of the ability of circRNAs . 
Protein coding:
head have been recently reported to encode proteins. Both of these circRNAs were able to interact with ribosomes and et al site (IRES) and lead to translation initiation .
Identification of circular RNAs as important regulators of cardiovascular development and disease and were thought to be generated by RNA splicing errors or be were revealed to function as molecular sponges for miRs after miRs and lncRNAs. Slc8a1 is known to be a sodium/ calcium exchanger that is critical for heart development and contraction . Rhobtb3 the heart . A study focused on a human induced pluripotent ulators in cardiac development and function (eg atxn10, chd7, dnajc6 and slc8a1) study showed that circRNAs play important roles in pathways . . Dia reported to regulate the expression and function of alpha .
Circular RNAs in vascular development

Roles of circular RNAs in myocardial infarction
Roles of circular RNAs in cardiac senescence
sufficient to overcome cardiac damage once they are dif ferentiated into their mature forms. Cardiomyocytes also undergo pathological aging termed cardiac senescence. Du et al reported that exonic CircFoxo3 could induce cardiac senes cence . Exogenous CircFoxo3 could aggravate heart senes also provided mechanistic insights showing that CircFoxo3 promotes cardiac senescence by binding to inhibitor of dif
Roles of circular RNAs in atherosclerosis
Atherosclerosis is a vascular disease caused by injury to the vascular endothelium that leads to the accumulation of choles terol that eventually blocks the vessel. MI usually occurs when a blood clot blocks blood flow to the heart. Atherosclerosis could have a genetic predisposition due to its association with the ink4/arf tumor suppressor genes (p16ink4a p15ink4b and arf) and the of anril Review of recent patents filed on multiple circRNAs as potential CVD biomarkers.
expressed circRNAs as well as their utilities for the diagnosis used for new types of biomarkers that lead to novel diagnos that the circRNA transcripts in these patents could serve as biomarkers for the diagnosis of cardiovascular disorders. effects of these circRNAs on endothelial cell sprouting and failure and describes kits designed to diagnose MI using one or more anril the patent discusses methods for screening for compounds to prevent or treat such disorders . 
Conclusions and current & future developments
Very little is known about circRNAs and how they function and regulate multiple physiological and pathological pro in the clinical setting until enough knowledge is established about them . All of the previous studies involving human subjects contain only a small cohort of patients or healthy provide more convincing data on pathophysiological roles of circRNAs and their potential utilities as biomarkers. More mainly attributed to the absence of standardized methodolo of circRNAs as biomarkers for CVDs to the clinic somehow risky and not currently favorable for FDA approval.
to play important roles in the evolving strategies for tackling the tremendous promise of circRNAs in biomarker research. Although some circular RNA biomarkers for heart disease target effects. More work is needed to better validate and research directions may help deepen our knowledge of the roles of circRNAs in CVDs and addressing their value as bio markers. (i) A detailed characterization of circRNA biogenesis originating tissues for circulating circRNAs are unknown and to secondary effects. (iii) A characterization of the full spec trum of circulating circRNAs in the bloodstream would guide in selecting candidate circRNAs for future biomarker stud circRNA detection would be needed for developing clinically tive approaches between basic scientists and clinicians will be ities.
